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ABSTRACT
Introduction: The effectiveness of hyperbaric
oxygen therapy (HBOT) on selected diabetic
foot wounds continues to be controversial. A
holistic approach to diabetes and its
comorbidities may be beneficial in the
discussion of the proper application of this
treatment modality. The aim of the current
study is to evaluate the efficacy of HBOT on
diabetic foot wounds and provide clinical data
that may support this knowledge.
Methods: The present study was a retrospective
analysis of the effect of HBOT on diabetic foot
lesions ranging 3–5 on the Wagner Grading
System. Patients had been treated with HBOT
and monitored for 12 months. The results were
analyzed in relation to age, gender, diabetes
duration and type, microangiopathic
complications, peripheral arterial disease
(PAD), history of coronary artery disease,
stroke, hypertension, smoking habits, glycated
hemoglobin, blood sedimentation rate,
C-reactive protein, and number of HBOT
sessions. Microangiopathies were evaluated as
retinopathy, nephropathy, and neuropathy.
PAD was determined by available color
Doppler ultrasonography and/or angiographic
data depending on a modified scoring system.
The data of arteries from the aorta to the dorsal
pedal artery were scored singly. Average scores
of aorto-iliac, femoral, popliteal and pedal levels
were also evaluated with this system to compare
the healing results in relation to PAD.
Results: One hundred and seventeen patients
with 126 diabetic foot wounds were treated.
Histories of coronary artery disease, stroke, and
non-proliferative or proliferative retinopathy
had negative effects on HBOT (P = 0.002,
P = 0.015, P = 0.022, respectively). Depending
on the scorings of PAD, the single arterial scores
and average scores of aorto-iliac, popliteal and
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pedal levels had no relation to outcomes, while
the average scores of the femoral arterial level
affected the results (P = 0.048).
Conclusions: Diabetic foot patients with
histories of coronary artery diseases or stroke
and non-proliferative or proliferative
retinopathy might resist HBOT. PAD at the
femoral arterial level has been shown to have a
significant negative effect on HBOT outcomes
that should be first considered for surgery. In
contrast, PAD below the knee does not seem to
be an obstacle to the efficacy of HBOT.
Keywords: Comorbidities; Diabetic foot;
Hyperbaric oxygen; Macrovascular
complications; Microvascular complications;
Peripheral arterial disease; Wound healing;
Retinopathy
INTRODUCTION
Diabetic foot is a worldwide problem that
causes morbidity and mortality together with
high costs. Nearly 20% of ulcers are reported as
non-healing despite standard care [1, 2].
Hyperbaric oxygen therapy (HBOT) is a
systemic method to provide extra oxygen to
tissues. This therapy achieves sufficient oxygen
concentrations for infected hypoxic tissues, and
can therefore be added to the treatment of
problematic wounds, such as diabetic foot [3].
HBOT enhances neutrophil killing ability and
the effect of antibiotics, fibroblast activity,
collagen synthesis, and stimulates angiogenesis
[4]. Although this treatment is recommended
with moderate-quality evidence [5, 6], the
effectiveness of HBOT on selected diabetic foot
wounds still encounters controversy partly
because of a history of unsubstantiated claims
of its effectiveness in treating a variety of
ailments [7]. The complexities of diabetes itself
and also of the wounds make prospective,
double blind, randomized-controlled trials
difficult [1]. There are a few studies including
prospective controlled trials on the use of HBOT
in diabetic foot [8–13]. The conclusions might
be confusing depending on the characteristics
of the wounds or the patients with different
weighted complications.
The authors of the current study planned to
retrospectively evaluate the effect of HBOT on
the diabetic foot problem on a wide range of
complicated patients. The aim was to discover
the role of comorbidities as limiting factors on
the effect of hyperbaric oxygen in cases of
diabetic foot and to access the clinical data that
may support that knowledge.
METHODS
Patients with diabetic foot wounds were referred
to a private, single hyperbaric center and treated
with HBOT, mostly as outpatients. Patients were
treated conventionally including glycemic
control, antibiotherapy, debridement of
nonviable tissue and proper wound care at
least 2 weeks prior to being referred for HBOT.
The reason for referral was no response or
worsening of symptoms despite the above
measures, or minor amputations in ischemic/
neuroischemic diabetic foot. Patients in this
group were not referred if they had just
undergone vascular intervention. For
neuropathic diabetic foot ulcers, the same
treatments were applied at least 1 month prior
to the start of HBOT. Patients who had just
undergone minor amputations in this group
were not accepted for HBOT. Patients who had
diabetes for less than 2 years or who also had
thromboangiitis obliterans or expansive
peripheral arterial disease with early diabetes
were also excluded from HBOT.
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Diabetic foot wounds were classified using
the Wagner Grading System [14] prior to HBOT.
Osteomyelitis was identified by plain
radiographs, magnetic resonance imaging or
scintigraphy. If the bone was exposed or
palpable with a probe, and had purulent
leakage, it was accepted to have osteomyelitis.
The demographic data of the patients,
diabetes type and duration, smoking habits,
history of coronary artery disease, stroke or
hypertension, blood sedimentation rates,
C-reactive protein (CRP), and glycated
hemoglobin (HbA1c) levels at the beginning of
HBOT were recorded.
Hyperbaric oxygen therapy sessions were
applied in a multiplace chamber (Haux
Starmed 2200/5,5; Haux Life Support GmbH,
Karlsbad-Ittersbach, Germany) daily, 6 days a
week, for a total of C20 sessions. All patients
were treated with the same HBOT treatment
table, consisting of three 25-min oxygen
periods, separated by two 5-min air breaks, for
a total of 120 min/session, at 2.4 atmosphere
absolute (ATA). A constant medical staff was in
charge of the patients’ medical management
and supervision.
Wound healing was observed at the end of
HBOT and 12 months following therapy. Mean
follow-up time was 25.6 ± 13.3 months
(minimum 6; maximum 52). Outcomes were
determined by wound healing results.
Complete wound closure and no leakage were
considered healing. Healing and minor
amputations were accepted as favorable. On
the other hand, no improvement or major
amputations were accepted as unfavorable.
Outcomes were analyzed at the end of HBOT
depending on the available macrovascular and
microvascular data. These outcomes were also
compared with the 12th month results.
Peripheral arterial disease (PAD), which was
determined by color Doppler ultrasonography
(DUS) and/or by angiographies, was analyzed. A
modified scoring system was created to provide a
numerical analysis of these tests, depending on
previously reported assessment methods [15–17].
The schemes determining the levels and
occlusion degrees within the recommended
standards for reports dealing with lower
extremity ischemia were utilized to assess the
angiographic data of the current study [15]. DUS
data were scored depending on the arterial flow
characteristics. Furthermore, angiographic
scoring degrees were inverted to synchronize the
values obtained from color DUS data as follows.
Patients who had triphasic waveforms or
normal calibration in all arteries from the aorta
to the dorsal pedal artery were accepted to be
free of PAD, while others were considered to
have PAD. Triphasic waveforms on color DUS
and/or normal calibration in angiography were
scored as 3 points. Biphasic waveform and/or
stenosis greater than 50% was scored as 2
points; monophasic waveform and/or
circulation by collateral arteries was scored as
1 point. If there was a total occlusion, it was
scored as 0 points. Scores were recorded for each
artery from the aorta to dorsal the pedal artery.
The average scores of these data were also
calculated in four levels as follows:
1. Aorto-iliac (abdominal aorta, common, and
external iliac arterial scores).
2. Femoral (common, superficial, and deep
femoral arterial scores).
3. Popliteal (popliteal, anterior–posterior tibial
arterial scores).
4. Pedal (dorsal pedal artery and plantar arc
scores).
The relationship of PAD to wound healing of
HBOT-treated patients was evaluated depending
on these scores. These patients were also
evaluated on their vascular interventions
which were decided by surgeons that the
patients consulted.
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Patients’ microangiopathic and
atherosclerotic characteristics were recorded
depending on their data given.
Microangiopathies were evaluated as
retinopathy, nephropathy, and neuropathy.
Retinopathy was analyzed in two groups:
background retinopathy in one group, and
non-proliferated diabetic retinopathy (NPDR)
and proliferated diabetic retinopathy (PDR)
retinopathy in another group (advanced
retinopathy). Nephropathy was analyzed in
three groups: normoalbuminuria in one group;
microalbuminuria (30–300 mg/24 h) in the
second; macroalbuminuria ([300 mg/24 h) and
end-stage renal disease in the third group.
Neuropathy was determined positive if there
was a pressure sore or Charcot foot or if the
wound occurred due to insensate burn; or if
vibratory sensation in the feet was lost. The
monofilament test was not used. All
microangiopathic data were also studied
separately regarding their relations to the
outcomes.
The only reported adverse reactions were
barotraumatic otitis in 12 patients and a
hypoglycemic event in one patient.
Statistical Analysis
For continuous variables, an independent
samples t test was performed to compare the
means of two groups. A Mann–Whitney U test
was used to compare the two groups for non-
parametric data (PAD scorings). A marginal
homogeneity test was used to determine the
difference of categorical variables between
measurements (outcomes at the end of HBOT
and at the 12-month follow-up). Pearson’s Chi
square test, Yates’ Chi square test, or Fisher
exact tests were used to examine the difference
between groups for categorical variables. A
logistic regression analysis was performed to
analyze the association between the dependent
variable (outcomes at the end of HBOT) and
independent variables (demographic data,
diabetes type and duration, active smoking,
history of coronary artery disease, stroke or
hypertension, neuropathy, end-stage renal
disease and non-proliferative/proliferative
retinopathy). The stepwise method was used
in the logistic regression analysis. Using the
logistic models, odds ratios (OR) and their
respective 95% confidence intervals (CIs) were
calculated. A value of P\0.05 was accepted as
statistically significant. Data analysis was
performed using the SPSS 15.0 (Statistical
Package for Social Sciences, SPSS Inc. Chicago,
IL, USA) software package.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study.
RESULTS
One hundred and seventeen patients were
reviewed, nine of which were readmitted to
the hyperbaric center at least 1 year later
because of a subsequent wound and these
patients were counted twice. Therefore, 126
diabetic foot lesions were evaluated. There were
84 Wagner grade 3, 41 grade 4, and one grade 5
diabetic foot lesions assessed. Of these wounds,
68 (54.0%) were ischemic, six (4.8%) were
neuroischemic, 40 (31.7%) were neuropathic
non-ischemic, and 12 (9.5%) were neither
ischemic nor neuropathic.
The mean age of patients was 59.3 ± 11.4 (84
male, 42 female), mean duration of diabetes was
16.8 ± 8.1 years, eight patients had type 1
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diabetes and the remaining had type 2 diabetes.
Outcomes of HBOT were not related to any of
these parameters (Table 1).
There were 54 (42.8%) of patients with a
history of coronary artery disease and 20
(15.9%) patients with a history of stroke.
These characteristics demonstrated statistically
significant relationships to the outcomes of
HBOT (P = 0.002, OR 3.876 and P = 0.015, OR
4.857, respectively). Patients with a history of
coronary artery disease had a 3.88-fold risk of
non-healing or major amputation (95% CI
1.64–9.16); patients with a history of stroke
had a 4.86-fold risk of non-healing or major
amputation (95% CI 1.37–17.28) compared to
the other patients with no history. Logistic
regression analysis did not reveal any
relationship between other comorbidities such
as hypertension, active smoking, and presence
of neuropathy, advanced retinopathy, or end-
stage nephropathy and HBOT outcomes
(Table 1).
Cigarette pack/years (38.2 ± 33.6), HbA1c
(8.9 ± 1.9%), blood sedimentation rates
(83.3 ± 37 mm/h), CRP levels (60.7 ± 62.9) and
number of HBOT sessions (47 ± 23.9) had no
statistically significant effects on wound healing
results (Table 1).
Hyperbaric oxygen therapy was applied for
47 ± 23.9 (minimum: 20, median: 42) sessions.
At the end of HBOT, 39.6% wounds were healed
completely, 20.6% received minor amputation,
27.0% showed no improvement and 12.7%
received major amputation. There were no
statistically significant differences of the
wound healing results compared with the
12-month follow-up results excluding patients
who passed away within this period (P = 0.214,
Table 2).
Peripheral arterial disease was determined by
angiographic and/or color Doppler
ultrasonographic data in 86 patients. Twenty-











Mean age ± SD 59.3 ± 11.4 n.s.
Sex M/F 84/42 n.s.
Mean diabetes duration
(years) ± SD
16.8 ± 8.1 n.s.
Type 1/type 2 DM 8/118 n.s.
Neuropathy ?/total 103/126 n.s.
ESRD/total 33/126 n.s.
NPDR and PDR/total 91/107 n.s.
History of coronary artery
dis.
54 (42.9%) 0.002
History of stroke 20 (15.9%) 0.015
Hypertension 73 (57.9%) n.s.
Active smokers 67 (53.2%) n.s.
Independent sample t testc
Mean cigarette
pack/year ± SD
38.2 ± 33.6 n.s.
Mean HbA1c (%) ± SD 8.9 ± 1.9 n.s.
Mean sedimentation
(mm/h) ± SD
83.3 ± 37 n.s.
Mean CRP (mg/dl) ± SD 60.7 ± 62.9 n.s.
Mean number of HBO
sessions ± SD
47 ± 23.9 n.s.
CRP C-reactive protein, DM diabetes mellitus, ESRD
End-stage renal disease, HbA1c glycated hemoglobin,
HBOT hyperbaric oxygen therapy, NPDR non-
proliferative diabetic retinopathy, n.s. non-signiﬁcant,
PDR proliferative diabetic retinopathy
a Outcomes were consisted of healed or minor amputated
patients in the favorable group; non-healed or major
amputations in the unfavorable group
Statistical analysis method used was: b logistic regression, c
independent sample t test
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seven of these patients had normal arterial
conditions while the remaining had PAD.
Most of the patients with PAD were not
operated on because a lack of optimal vascular
interventions. Among these 51 non-operated
patients, 21 (41.2%) had atherosclerotic
changes placed below the knee, 30 (58.8%)
had these changes placed both above and below
the knee (Fig. 1).
Depending on the modified scoring system,
no significant relationship between the
outcomes and the arterial scorings was found
when each artery was evaluated singly.
However, when considered by average scorings
of four levels (aorto-iliac, femoral, popliteal,
and pedal), only the average of the femoral
arterial scores significantly affected the results
(P = 0.048, Table 3). The mean value of femoral
arterial scores was 2.77 ± 0.5 (median 3, min 1,
max 3) in the first (favorable) group and
2.64 ± 0.4 (median 2.67, min 1, max 3) in the
second (unfavorable) group.
The effect of microangiopathic
complications on the outcomes was also
studied separately. Advanced retinopathy
significantly affected the outcomes (P = 0.022,
Table 4). However, when nephropathy was
analyzed in three groups (normoalbuminuria,
microalbuminuria, and later stages) or in two
groups (end-stage renal disease and others), it
had no relation to the outcomes (P = 0.423
and P = 0.060, respectively). Similarly,
neuropathy (P = 0.706) had no relation to the
outcomes.
Table 2 Outcomes of HBOT
Status of patient At completion of HBOT n, %a At 12th month n, %a At 25.6 – 13.3 months n, %
Healed 50 (39.7%) 55 (49.1%) 46 (47.9%)
Minor amputation 26 (20.6%) 21 (18.8%) 20 (20.8%)
No improvement 34 (27.0%) 21 (18.8%) 15 (15.6%)
Major amputation 16 (12.7%) 15 (13.4%) 15 (15.6%)
Total wound 126 112 96
Deceased 0 14 30
Total patient 117 103 87
n number, HBOT hyperbaric oxygen therapy
a There were no statistically signiﬁcant differences for wound healing results at completion of HBOT and at the 12th
month (P = 0.214)
Fig. 1 Peripheral arterial condition of patients who have
angiographic and/or color DUS data. PAD was deter-
mined by color DUS and/or by angiographies. DUS
Doppler ultrasonography data, HBO hyperbaric oxygen,
PAD peripheral arterial disease, PTA percutaneous trans-
luminal angioplasty
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DISCUSSION
There are a few prospective controlled trials
about HBOT usage on diabetic foot. Although
conclusions are different in these studies, each
of them has been focused on different types of
wounds and patients [8–12]. The authors of the
current study retrospectively evaluated the
effect of HBOT on diabetic foot wounds in a
wide range of patients with varying
complications. The aim was to discover the
factors that affect the outcome of HBOT and to
understand the factors determining its efficacy.
Peripheral arterial disease is a known risk
factor for limb amputation in patients with
diabetes [18–20]. Angiographic and Doppler US
scoring are reported as assessment methods to
estimate the degree of PAD [15–17]. In the
present study, the researchers modified these
methods and evaluated the data of color DUSs
and/or angiographies of 86 patients. Although
ankle: brachial pressure scorings were shown to
be in close correlation with arteriographic
scorings [16], the researchers preferred to use
the flow characteristics of the arterial DUS data
because of the unreliability of the Doppler-
derived ankle: brachial index depending on
arterial media calcification of diabetic vascular
disease [21]. Furthermore, angiographic scoring
degrees were inverted to synchronize the values
obtained from color DUS. These modifications
allowed the assessments to be made together or
Table 3 Relation of PAD to HBOT outcomes





Aorto-iliac level (average) 0.963
Abdominal aorta 1.000
Common internal artery 0.707
External iliac artery 0.531
Femoral level (average) 0.048
Common femoral artery 0.185
Deep femoral artery 0.101
Superﬁcial femoral artery 0.070
Popliteal level (average) 0.215
Popliteal artery 0.277
Anterior tibial artery 0.996
Peroneal artery 0.398
Posterior tibial artery 0.069
Pedal level (average) 0.316
Dorsal pedal artery 0.347
Plantar arc 0.662
Relations of PAD to outcomes were analyzed depending
on Doppler US and/or angiographic data of 86 patients at
the end of HBOT
DUS Doppler ultrasonography, HBOT hyperbaric oxygen
therapy, PAD peripheral arterial disease
a These arterial tests were worked up as explained in the
text and scores at the levels shown in the table were
compared with the outcomes
b Outcomes were consisted of healed or minor amputated
patients in the favorable group; non-healed or major
amputated patients in the unfavorable group
Table 4 Relation of retinopathy to outcomes







Background retinopathy 11 (69%) 0 (0%) 4 (25%) 1 (6%) 16 (100%)
NPDR/PDR 30 (33%) 23 (25%) 26 (29%) 12 (13%) 91 (100%)
Total patients 41 23 30 13 107
There was a signiﬁcant relation of outcomes to retinopathy at the end of HBOT (P = 0.022)
HBOT hyperbaric oxygen therapy, NPDR non-proliferative diabetic retinopathy, PDR proliferative diabetic retinopathy
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separately by the two different methods
providing anatomic and hemodynamic
information.
Among the 51 non-operated PAD patients of
the current study, 21 (41%) had atherosclerotic
changes placed below the knee, 30 (58%) had
these changes placed both above and below the
knee (Fig. 1) in accordance to atherosclerosis of
diabetes [22, 23].
The present study used the arterial scorings
of these patients to compare the PAD
conditions and outcomes of those who were
treated with HBOT. The scorings of each artery
from the aorta to the pedal arteries were not
associated with the outcomes. Although not
significant, the P values related to the superficial
femoral and posterior tibial arterial scorings
(P = 0.070, P = 0.069, respectively) were
distinctly lower than other single arteries
(Table 3). On the other hand, depending on
the average scorings of the four arterial levels,
the results demonstrate that there is a
significant relationship to HBOT outcomes at
the femoral arterial level (P = 0.048, Table 3),
but not at the others. This suggests that
wherever atherosclerotic changes were placed,
only the femoral arterial locations affect the
outcomes of HBOT negatively. Therefore, in the
presence of femoral atherosclerotic lesions,
attention must be given to vascular
interventions before HBOT is initiated. In
contrast, PAD below the knee does not seem
to be an obstacle to the efficacy of HBOT in the
treatment of diabetic foot.
PAD is an expression of systemic
atherosclerotic disease. Therefore, the
researchers of the current study evaluated the
patients’ histories of coronary artery disease,
hypertension, stroke, and smoking habits to
assess the other data related to atherosclerosis. A
history of coronary artery disease and stroke has
been demonstrated to worsen wound healing of
the diabetic foot patients treated with HBOT
(P = 0.002 and P = 0.015, respectively). This is
true about coronary artery disease, regardless of
HBOT [1, 24]. Faglia et al. [25] demonstrated
prior instances of stroke to be a prognostic
determinant of major amputation in patients
treated with or without HBOT. In conclusion,
one should take coronary artery disease and
stroke history into consideration because of
their possible negative effect on expected
outcome.
Microvascular complications are other
comorbidities that affect wound healing of
patients with diabetes. The current study
evaluated the relationships of HBOT outcomes
to neuropathy, nephropathy, and retinopathy.
Although neuropathy was not shown to affect
the outcomes significantly, the quality of this
argument is poor. A strong association with both
diabetic foot ulceration and lower extremity
amputation has been demonstrated with
chronic kidney disease and end-stage renal
disease [26, 27]. In the current study,
interestingly there was not a significant
relationship to chronic kidney disease or end-
stage renal disease. Despite a small amount of
missing data on retinopathy, the researchers
have demonstrated that HBOT outcomes were
significantly better when retinopathy was at a
background stage and poorer when it progressed
(P = 0.022, Table 4). One might hypothesize
that the progression of retinopathy might be
an early and more valuable marker when
discussing about the effect of HBOT on wound
healing. These data should be taken to
consideration in further trials as they can
provide clues about the mechanism of the
effect of HBOT on microcirculation which may
facilitate wound healing.
A long-term analysis of the effect of HBOT
on ischemic diabetic ulcers has shown that the
benefit of HBOT seemed to persist after
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discontinuing the therapy [9, 10]. These results
may greatly depend on the effect of
angiogenesis [8]. In accordance with this,
there were no statistically significant
differences of the favorable outcomes
compared with the 12-month follow-up results
excluding patients who passed away within this
period (Table 2).
Patients’ characteristics such as age, diabetes
duration and HbA1c were not shown to be
related to the outcomes, contrary to
expectations. This might be due to the
complexity of the other factors such as
comorbidities and the extent of PAD which
were shown to primarily affect healing [1].
A lack of a reliable assessment of the
neuropathy was a limitation of this study.
Diabetic foot off-loading techniques were
applied very poorly both before and with
HBOT. Retinopathy could have not been
evaluated in all patients. Transcutaneous
oxygen pressure (TcPO2) measurements which
may have been valuable were not made.
Diabetic foot should be considered a sign of
multi-organ disease. Therefore, before a
decision about HBOT has been reached, an
overall understanding of the patients’ condition
of diabetes, as well as the wound, is required.
The current study demonstrates that histories of
coronary artery disease or stroke, and advanced
retinopathy worsen the outcomes of HBOT
significantly. The results also revealed that
PAD at the femoral level should be first
considered for surgery, but PAD below the
knee seems not to be an obstacle to the effect
of HBOT in the treatment of diabetic foot.
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